NIH R01 · 2024
Responses to Hybrid Insulin Peptides as Biomarkers of Disease Activity in Human Type 1 Diabetes
Abstract: T Cell Responses to Hybrid Insulin Peptides as Biomarkers of Disease Activity in Type 1 Diabetes An important objective in T1D research is the investigation of autoantigens that activate effector T cells and trigger the inflammatory process in islet beta-cells. We recently identified Hybrid Insulin Peptides (HIPs) as a new class of autoantigens in type 1 diabetes (T1D). These neoantigens are created by the fusion of insulin fragments with peptides from other secretory granule proteins such as chromogranin A (ChgA), islet amyloid polypeptide (IAPP), neuropeptide Y (NPY) or insulin itself. Because insulin is present only in pancreatic beta cells, this discovery might provide an…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.